Bibliography
- Frisardi V, Solfrizzi V, Imbimbo BP, Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid. Curr Alzheimer Res 2010;7:40-55
- Mangialasche F, Solomon A, Winblad B, Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010:9:702-16
- Panza F, Solfrizzi V, Frisardi V, Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging 2009;26:537-55
- Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008;60:534-42
- Walter J, Kaether C, Steiner H, Haass C. The cell biology of Alzheimer's disease: uncovering the secrets of secretases. Curr Opin Neurobiol 2001;11:585-90
- Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12:383-8
- Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008;192:106-13
- Koffie RM, Meyer-Luehmann M, Hashimoto T, Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 2009;106:4012-17
- Shankar GM, Bloodgood BL, Townsend M, Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007;27:2866-75
- Lesne S, Koh MT, Kotilinek L, A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006;440:352-7
- Lee EB, Leng LZ, Zhang B, Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 2006;281:4292-9
- Lambert MP, Velasco PT, Chang L, Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 2007;100:23-35
- Imbimbo BP, Panza F, Frisardi V, Therapeutic intervention for Alzheimer's disease with gamma-secretase inhibitors: still a viable option? Expert Opin Investig Drugs 2011;20:325-41
- Lannfelt L, Blennow K, Zetterberg H, PBT2-201-EURO study group. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008;7:779-86
- Faux NG, Ritchie CW, Gunn A, PBT2 rapidly improves cognition in Alzheimer's disease: additional Phase II analyses. J. Alzheimers Dis 2010;20:509-16
- Wisniewski T, Konietzko U. Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol 2008;7:805-11
- Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010;6:108-19
- Panza F, Frisardi V, Imbimbo BP, Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy 2010;2:767-82
- Jicha GA. Is passive immunization for Alzheimer's disease ‘alive and well’ or ‘dead and buried’? Expert Opin Biol Ther 2009;9:481-91
- Lichtlen P, Mohajeri MH. Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. J Neurochem 2008;104:859-74
- Kerchner GA, Boxer AL. Bapineuzumab. Expert Opin Biol Ther 2010;10:1121-30
- Samadi H, Sultzer D. Solanezumab for Alzheimer's disease. Expert Opin Biol Ther 2011;11:787-98
- Siemers ER, Friedrich S, Dean RA, Safety and changes in plasma and cerebrospinal fluid amyloid-beta after a single administration of an amyloid-beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010;33:67-73
- DeMattos RB, Racke MM, Gelfanova V, Identification, characterization, and comparison of amino-terminally truncated Abeta42 peptides in Alzheimer's disease brain tissue and in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment. Alzheimers Dement 2009;5(Suppl 1):P156-7
- Seubert P, Barbour R, Khan K, Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener Dis 2008;5:65-71
- Siemers ER, Friedrich S, Dean RA, P4-346: safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease. Alzheimers Dement 2008;4(Suppl 2):T774
- Black RS, Sperling RA, Safirstein B, A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010;24:198-203
- Salloway S, Sperling R, Gilman S, A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-70
- Rinne JO, Brooks DJ, Rossor MN, 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-72
- Racke MM, Boone LI, Hepburn DL, Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005;25:629-36
- Eli Lilly and Co. Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION). ClinicalTrials.gov NCT00905372. Available from: http://clinicaltrials.gov/ct2/show/NCT00905372?term=NCT00905372&rank=1
- Eli Lilly and Co. Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION2). ClinicalTrials.gov NCT00904683. Available from: http://clinicaltrials.gov/ct2/show/NCT00904683?term=NCT00904683&rank=1
- Eli Lilly and Co. Continued safety monitoring of solanezumab in Alzheimer's disease (EXPEDITION EXT). ClinicalTrials.gov NCT01127633. Available from: http://clinicaltrials.gov/ct2/show/NCT01127633?term=NCT01127633&rank=1
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC. Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier). ClinicalTrials.gov NCT00575055. Available from: http://clinicaltrials.gov/ct2/show/NCT00575055?term=NCT00575055&rank=1
- Wyeth. Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients. ClinicalTrials.gov NCT00676143. Available from: http://clinicaltrials.gov/ct2/show/NCT00676143?term=NCT00676143&rank=1
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC. Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier). ClinicalTrials.gov NCT00574132. Available from: http://clinicaltrials.gov/ct2/show/NCT00574132?term=NCT00574132&rank=1
- Wyeth. Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab. ClinicalTrials.gov NCT00916617. Available from: http://clinicaltrials.gov/ct2/show/NCT00916617?term=NCT00916617&rank=1
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC. Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease. ClinicalTrials.gov NCT01254773. Available from: http://clinicaltrials.gov/ct2/show/NCT01254773?term=NCT01254773&rank=1
- Wyeth. Study Evaluating Bapineuzumab In Alzheimer Disease Subjects. ClinicalTrials.gov NCT00663026. Available from: http://clinicaltrials.gov/ct2/show/NCT00663026?term=NCT00663026&rank=1
- Pfizer. Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers. ClinicalTrials.gov NCT01005862. Available from: http://clinicaltrials.gov/ct2/show/NCT01005862?term=NCT01005862&rank=1
- Pfizer. Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease. ClinicalTrials.gov NCT01125631. Available from: http://clinicaltrials.gov/ct2/show/NCT01125631?term=NCT01125631&rank=1
- Pfizer. Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease. ClinicalTrials.gov NCT00722046. Available from: http://clinicaltrials.gov/ct2/show/NCT00722046?term=NCT00722046&rank=1
- Pfizer. A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease. ClinicalTrials.gov NCT00945672. Available from: http://clinicaltrials.gov/ct2/show/NCT00945672?term=NCT00945672&rank=1
- Genentech. A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease. ClinicalTrials.gov NCT00736775. Available from: http://clinicaltrials.gov/ct2/show/NCT00736775?term=NCT00736775&rank=1
- Hoffmann-La Roche. A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease. ClinicalTrials.gov NCT01224106. Available from: http://clinicaltrials.gov/ct2/show/NCT01224106?term=NCT01224106&rank=1
- Hoffmann-La Roche. A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease. ClinicalTrials.gov NCT00531804. Available from: http://clinicaltrials.gov/ct2/show/NCT00531804?term=NCT00531804&rank=1
- GlaxoSmithKline. A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease. ClinicalTrials.gov NCT00459550. Available from: http://clinicaltrials.gov/ct2/show/NCT00459550?term=NCT00459550&rank=1
- Eisai, Inc. A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study. ClinicalTrials.gov NCT01230853. Available from: http://clinicaltrials.gov/ct2/show/NCT01230853?term=NCT01230853&rank=1
- Britschgi M, Olin CE, Johns HT, Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci USA 2009;106:12145-50
- Weksler ME, Relkin N, Turkenich R, Patients with Alzheimer's disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002;37:943-8
- Effros RB, Fletcher CV, Gebo K, Workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008;47:542-53
- Holmes C, Boche D, Wilkinson D, Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216-23
- Castellani RJ, Lee HG, Siedlak SL, Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis 2009;18:447-52
- Medina M. Recent developments in tau-based therapeutics for neurodegenerative diseases. Recent Pat CNS Drug Discov 2011;6:20-30
- Rosenmann H, Grigoriadis N, Karussis D, Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 2006;63:1459-67
- Boimel M, Grigoriadis N, Lourbopoulos A, Efficacy safety of immunization with phosphorylated tau against neurofibrillary and tangles in mice. Exp Neurol 2010;224:472-85
- Novak M. Tau vaccine: active immunization with misfloded tau protein attenuates tau pathology in the transgenic rat model of tauopathy. Alzheimers Dement 2009;5(Suppl 1):P93
- Kontsekova E, Ivanovova N, Handzusova M, Novak M. Chaperone-like antibodies in neurodegenerative tauopathies: implication for immunotherapy. Cell Mol Neurobiol 2009;29:793-8
- Zilka N, Kontsekova E, Novak M. Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathies. J Alzheimers Dis 2008;15:169-79
- Bretteville A, Planel E. Tau aggregates: toxic, inert, or protective species? J Alzheimers Dis 2008;14:431-6
- Congdon EE, Duff KE. Is tau aggregation toxic or protective? J Alzheimers Dis 2008;14:453-7
- Walsh DM, Selkoe DJ. Abeta oligomers – a decade of discovery. J Neurochem 2007;101:1172-84
- Kayed R, Jackson GR. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Curr Opin Immunol 2009;21:359-63
- Dubois B, Feldman HH, Jacova C, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-46
- Dubois B, Feldman HH, Jacova C, Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118-27
- Wyeth. Study Evaluating the Efficacy and Safety of Bapineuzumab in Alzheimer Disease Patients. ClinicalTrials.gov NCT00667810. Available from: http://clinicaltrials.gov/ct2/show/NCT00667810?term=NCT00667810&rank=1
- Wyeth. A Long-Term Safety and Tolerability Study of Bapineuzumab in Alzheimer Disease Patients. ClinicalTrials.gov NCT00996918. Available from: http://clinicaltrials.gov/ct2/show/NCT00996918?term=NCT00996918&rank=1
- Wyeth. A Long-Term Safety and Tolerability Extension Study of Bapineuzumab in Alzheimer Disease Patients. ClinicalTrials.gov NCT00998764. Available from: http://clinicaltrials.gov/ct2/show/NCT00998764?term=NCT00998764&rank=1
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC. A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease. ClinicalTrials.gov NCT00937352. Available from: http://clinicaltrials.gov/ct2/show/NCT00937352?term=NCT00937352&rank=1
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease NCT00606476. Available from: http://clinicaltrials.gov/ct2/show/NCT00606476?term=NCT00606476&rank=1